Business briefs: Quintiles and Forest, plus Paula Watch

Share this article:

Quintiles has purchased CRO Novella Clinical. The deal will bring Novella's oncology, medical device and diagnostic trials into the Quintiles portfolio, but Novella will operate as a stand-alone unit.

Forest and Almirall are delaying an experimental COPD drug submission to the FDA. The drug is a combination of two bronchodilators, and the companies said in a statement Thursday that in pre-NDA discussions with the FDA, that the regulator had questions about “resolving chemistry, manufacturing and control specifications.” The two-for-one drug combines aclidinum bromide, known by the brand name Tudorza, and formoterol fumarate.

Paula Watch: Paula Deen's rebound may have begun. One day after a judge threw out racism claims against the former Food Network star, Savannahnow.com reports that the celebrity chef may have a cameo on her son's show "Home for Dinner with Jamie Deen." Savannahnow.com notes that it is unclear if the episode was filmed before Deen's reputation began to plummet.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters